June 11, 2020 Clinical Research/Diagn. Life Science Tools Product Launch

PCR Biosystems launches 4x RT-qPCR kit to enable ultra-sensitive, high-throughput detection of viral RNA sequences

Caption: New qPCRBIO Probe 1-Step Virus Detect. Click images to download. London, UK (11 June 2020) – PCR Biosystems, the UK-based PCR experts, today announced the launch of qPCRBIO Probe 1-Step Virus Detect, a high-concentration 4x RT-qPCR kit designed specifically for ultra-sensitive, high-throughput detection of viral RNA sequences, including SARS-CoV-2. The new kit, which marks the latest... Read more

June 10, 2020 Acad, Gov/Utilities Clinical Research/Diagn. Environ, Ag./Food & Bev Life Science Tools PR/Corporate

Illumina Receives First FDA Emergency Use Authorization for a Sequencing-Based COVID-19 Diagnostic Test

SAN DIEGO–(BUSINESS WIRE)–Illumina, Inc. (NASDAQ: ILMN) is paving the way for large-scale, next-generation sequencing-based (NGS) COVID-19 testing. Today, the U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for the Illumina COVIDSeq™ Test, a high-throughput, sequencing-based, in vitro diagnostic (IVD) workflow enabling the detection of SARS-CoV-2. The end-to-end workflow extends the options... Read more

June 9, 2020 Clinical Research/Diagn. M&A, Partnerships

Bio-Techne and Zero – The End of Prostate Cancer Announce Partnership to Fund Education and Awareness Campaigns to Empower Men With Prostate Cancer

MINNEAPOLIS, June 11, 2020 /PRNewswire/ — Bio-Techne Corporation (NASDAQ:TECH) today announced that Exosome Diagnostics, a Bio-Techne brand, has established a new partnership with ZERO – The End of Prostate Cancer, the leading national nonprofit organization in the fight against prostate cancer. ZERO advances research, improves the lives of men and families, and inspires action for patients,... Read more

June 9, 2020 Clinical Research/Diagn. Licensing, IP, and Legal

Promega Microsatellite Instability Molecular Test, OncoMate™ MSI Dx Analysis System, CE Marked and Available in Europe

New diagnostic test for MSI in solid tumors can inform physicians on immuno-oncology therapies and can guide treatment decisions for patients with Lynch-associated cancers Leiden, Netherlands and Madison, WI USA. (June 9, 2020) Promega Corporation today announced CE marking for the OncoMate™ MSI Dx Analysis System(OncoMate™ MSI) as a new in vitro diagnostic (IVD) medical device in Europe.... Read more

June 3, 2020 Clinical Research/Diagn. Life Science Tools M&A, Partnerships

Swift Biosciences and Arbor Biosciences Partner on Targeted NGS Workflows for Coronavirus

ANN ARBOR, Mich. June 3, 2020 /PRNewswire/ — Swift Biosciences and Arbor Biosciences, a division of Chiral Technologies, jointly announced a partnership to offer a complete workflow for RNA-Seq library preparation and targeted enrichment of the SARS-CoV-2 genome. An enabling offering for epidemiological research and public health surveillance, the partnership leverages Swift’s patented Adaptase® technology... Read more

May 28, 2020 Clinical Research/Diagn. Life Science Tools Product Launch

Swift Biosciences Enables COVID-19 Surveillance With NGS of Low Titer SARS-CoV-2 Specimens

ANN ARBOR, Mich. – May 28, 2020 — Swift Biosciences, Inc., a leader in commercialization of DNA and RNA library preparation kits for Next-Generation Sequencing (NGS), has announced the release of its Swift Normalase™ Amplicon Panel (SNAP) SARS-CoV-2 kit. Targeting the full viral genome in a single tube reaction with a rapid 2-hour workflow, Swift’s... Read more